Valentin Maurer

Valentin Maurer

Auto-generated profile, based on publicly available information

Valentin Maurer

Translational Cancer Epigenomics, Division of Translational Medical Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 February 2022 in Frontiers in Surgery
Verified
Journal Article
Open access
VMValentin Maurer
Valentin Maurer
MHMarian Howaldt
Marian Howaldt
IFInga Feldmann
Inga Feldmann
TLTim Ludwig
Tim Ludwig
MVMalte W. Vetterlein
Malte W. Vetterlein
SRSilke Riechardt
Silke Riechardt
Objectives: Numbers of PIV are rising. The aim of this study is to analyze the surgical learning-curve (LC) on the grounds of perioperative complications.Patients and Methods: 108 PIVs, performed by a single surgeon between 2015 and 2018 have been analyzed. Learning-curve analysis was based on three factors: operating time, vaginal depth and complications.Results: The median FU was 6.3 months. Median age at surgery was 36 years, median time of hormone treatment was 36 months. The median CI was 0.3 and the median BMI was 25 kg/cm3. Median CCI® was 8.08. 40.7% of the patients developed short-term complications, more than half of which were Clavien I. Overall only 1.9% had Clavien IIIb complications. There were no Clavien IV or V complications. 17.6% of patients had wound infections, 13% wound dehiscence, 9.3% introitus strictures, 13.9% suffered from atrophy of the neovagina, i.e. loss of depth or width, and 8.3% from meatus urethrae strictures. Duration of hormonal therapy, BMI and CI had no impact on surgical outcome. Age had a significant impact on CCI®, as younger patients had a higher risk for complications. Use of scrotal skin and surgeries performed had a significant influence. LC analysis via CUSUM analysis showed that after 32 surgeries, the PIV is performed safely.Conclusion: The PIV is a safe GAS-technique, associated with minor complications leading to low rates of revision surgery. Younger age, the use of scrotal skin and surgeon's experience has significant impact on complications. Duration of hormonal therapy, circumcision and BMI has no impact on complications.

17 August 2021 in Urologia Internationalis
Verified
Journal Article
Closed access
PDF file
HYHang Yu
Hang Yu
PGPhilipp Gild
Philipp Gild
RARaisa S. Abrams-Pompe
Raisa S. Abrams-Pompe
MVMalte W. Vetterlein
Malte W. Vetterlein
TLTim A. Ludwig
Tim A. Ludwig
CMChristian Paul Meyer
Christian Paul Meyer
Objective: The aim of the study was to compare procedural efficacy, early and late functional outcomes in holmium laser enucleation of the prostate (HoLEP) under spinal anesthesia (SA) versus general anesthesia (GA). Methods: We retrospectively reviewed patients undergoing HoLEP at our institution between 2012 and 2017. Standard pre-, peri-, and postoperative characteristics were compared according to anesthetic technique. Multivariable logistic regression analyses (MVAs) were employed to study the impact of SA on procedural efficacy and postoperative complications. Results: Our study cohort consisted of 1,159 patients, of whom 374 (32%) underwent HoLEP under SA. While a medical history of any anticoagulation/antiplatelet therapy except low-dose acetylsalicylic acid was significantly more common among patients undergoing GA (16% vs. 10%, p = 0.001), no other significant differences in preoperative characteristics were noted including age, body mass index, American Society of Anesthesiologists Classification (ASA), prostate size, or International Prostate Symptom Score (IPSS), and quality of life scores. Patients under SA exhibited shorter times of enucleation 42 min (interquartile range [IQR]:27–59 vs. 45 min [IQR: 31–68], p = 0.002), and combined time of enucleation/morcellation/coagulation (57 min [IQR: 38–85] vs. 64 min [IQR: 43–93], p = 0.002), as well as fewer complications (Clavien-Dindo ≥3) (12 [3.2%] vs. 55 [7%], p = 0.013). These associations were confirmed in MVA. Patients did not differ significantly with regard to early micturition including post-void residual volume and maximum flow-rate improvement. At a median follow-up of 33 months (IQR: 32–44), patients with SA had a lower IPSS score (median 3 [IQR: 1–6] vs. 4 [IQR: 2–7], p = 0.039). However, no significant differences were observed with respect to any urinary incontinence, urge symptoms, and postoperative pain. Conclusion: In this large retrospective series, HoLEP under SA was a safe and efficacious procedure with comparable early and long-term functional outcomes.

5 December 2025 in Blood Cancer Discovery
Verified
Journal Article
Closed access
MHMark Hartmann
Mark Hartmann
MSMaximilian Schönung
Maximilian Schönung
JRJovana Rajak
Jovana Rajak
VMValentin Maurer
Valentin Maurer
LHLing Hai
Ling Hai
DLDaniel Lipka
Daniel Lipka
Persistent fetal gene expression in childhood neoplasms is usually explained by a maturation block originating in the prenatal phase. In contrast, reactivation of fetal genes in adult malignancies is considered a consequence of oncofetal reprogramming (OFR) and is associated with aggressive disease. By reconstructing epigenetic ontogeny in juvenile myelomonocytic leukemia (JMML), we identified a postnatal maturation state of JMML stem cells with high transcriptional plasticity indicative of OFR in high-risk disease. Similarly, postnatal activation of oncogenic signaling by inducible Ptpn11E76K mutation in mice triggered molecular plasticity and reactivation of fetal gene expression. Integrative multi-omics analysis revealed aberrant CD52 expression as a feature of high-risk JMML stem cells. Anti-CD52 treatment depleted JMML stem cells and blocked disease propagation in xenograft models. Our results challenge the prevailing maturation block model of pediatric leukemogenesis and establish RAS-associated stem cell plasticity as a determinant of OFR and potential therapeutic vulnerabilities in high-risk JMML. Significance: Persistent fetal gene expression in pediatric malignancies is considered a consequence of prenatal maturation blockade. In this study, we demonstrate that oncogenic PTPN11 mutations enhance cellular plasticity. This leads to partial restoration of fetal molecular programs, creating new therapeutically exploitable vulnerabilities. See related commentary by Miao and Xu, pp. 168

28 May 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
VMValentin J. Maurer
Valentin J. Maurer
MSMarc Siggel
Marc Siggel
RJRasmus K. Jensen
Rasmus K. Jensen
JMJulia Mahamid
Julia Mahamid
JKJan Kosinski
Jan Kosinski
WPWeria Pezeshkian
Weria Pezeshkian
Simulating entire cells represents the next frontier of computational biology. Achieving this goal requires methods that accurately describe cellular membranes across spatial and temporal scales. Although three-dimensional electron microscopy enables detailed membrane visualization, limitations on acquisition geometry, data quality, and field-of-view often result in fragmented membrane representations incompatible with simulations. To resolve this, here we introduce Helfrich Monte Carlo Flexible Fitting (HMFF), an approach that integrates experimental density data into physical simulations to determine membrane structure. Through the accompanying Mosaic software platform, we apply HMFF to influenza virus particles, Mycoplasma pneumoniae cells, and entire eukaryotic organelles. The resulting models enable multi-scale simulations spanning millions of lipids and proteins at experimentally determined positions, support quantitative morphological analysis, assess uncertainty in membrane localization, and reveal physical effects implicit in the data. Together, these capabilities establish a foundation for data-driven whole-cell simulations.

1 November 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
MHMark Hartmann
Mark Hartmann
MSMaximilian Schoenung
Maximilian Schoenung
JRJovana Rajak
Jovana Rajak
VMValentin Maurer
Valentin Maurer
LHLing Hai
Ling Hai
DLDaniel Lipka
Daniel Lipka
Aberrant fetal gene expression facilitates tumor-specific cellular plasticity by hijacking molecular programs of embryogenesis 1 . Persistent fetal gene signatures in childhood malignancies are typically explained by their prenatal origins 2–6 . In contrast, reactivation of fetal gene expression is considered a consequence of oncofetal reprogramming (OFR) in adult malignancies and is associated with aggressive disease 7–10 . To date, OFR has not been described in the context of childhood malignancies. Here, we performed a comprehensive multi-layered molecular characterization of juvenile myelomonocytic leukemia (JMML) and identified OFR as a hallmark of aggressive JMML. We observed that hematopoietic stem cells (HSCs) aberrantly express mixed developmental programs in JMML. Expression of fetal gene signatures combined with a postnatal epigenetic landscape suggested OFR, which was validated in a JMML mouse model, demonstrating that postnatal activation of RAS signaling is sufficient to induce fetal gene signatures. Integrative analysis identified the fetal HSC maturation marker CD52 as a novel therapeutic target for aggressive JMML. Anti-CD52 treatment depleted human JMML HSCs and disrupted disease propagation in vivo . In summary, this study implicates OFR, defined as postnatal acquisition of fetal transcription signatures, in the pathobiology of a childhood malignancy. We provide evidence for the direct involvement of oncogenic RAS signaling in OFR. Finally, we demonstrate how OFR can be leveraged for the development of novel treatment strategies. Highlights: ▪ Epigenomic and transcriptomic landscape of juvenile myelomonocytic leukemia (JMML) in the context of hematopoietic development. ▪ The presence of fetal transcription signatures in childhood malignancies is not indicative of a developmental maturation block. ▪ High-risk JMML is characterized by oncofetal reprogramming of postnatal hematopoietic stem cells (HSCs). ▪ RAS-pathway mutations induce fetal-like gene expression signatures in murine postnatal HSCs. ▪ The fetal maturation marker CD52 is a novel therapeutic target in high-risk JMML.

15 June 2025 in bioRxiv
Verified
Preprint
Open access
VMValentin J. Maurer
Valentin J. Maurer
LGLukas Grunwald
Lukas Grunwald
DKDante M. Kennes
Dante M. Kennes
LDLea Dietrich
Lea Dietrich
JKJan Kosinski
Jan Kosinski
Identifying macromolecular complexes in situ using cryo-electron tomography remains challenging, with low signal-to-noise ratios and heterogeneous backgrounds among the key limiting factors. By integrating prior knowledge on macromolecular localization, such as the preferred orientations of membrane-associated proteins, detection can be improved by constraining searches to biologically feasible orientations. However, previous approaches integrating such constraints fail to achieve both computational scalability to large and curved systems and accurate detection. To resolve this, here we present rejection sampling, a novel approach for integrating translational and rotational constraints into template matching. Using simulated influenza virus-like particles, we demonstrate that rejection sampling outperforms existing methods in terms of precision and recall. Our approach can uniquely integrate constraints at voxel resolution while being compatible with imaging filters such as the contrast transfer function, essential for accurate macromolecular localization. Rejection sampling thus provides a practical solution for macromolecular detection in large and curved systems.